DEBx Medical Receives COFEPRIS Market Approval in Mexico for DEBRICHEM®
Launching at AMCICHAC 2025 in Partnership with Biotechlives
AMSTERDAM and MEXICO CITY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- 2.5 million chronic wounds each year consume nearly 8% of Mexico’s healthcare budget.
Addressing this challenge, DEBx Medical announces that DEBRICHEM® has received market approval from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS). In partnership with Biotechlives SAPI, the company is now launching this advanced treatment in Mexico, a tool uniquely designed to reopen the path to healing in chronic wounds.
A New Standard in Wound Bed Preparation
DEBRICHEM® is a CE-marked Class IIb medical device designed for chemical debridement of chronic wounds. In just 60 seconds, it clears biofilm, infection, and devitalized tissue, rapidly creating a wound bed ready to heal. As an Advanced Wound Bed Preparation tool, it empowers subsequent therapies like NPWT, grafts, and advanced dressings to work more effectively.
A Media Snippet accompanying this announcement is available by clicking on this link.
Clinical studies demonstrate DEBRICHEM®:
- Eradicates biofilms & microbial load within 60 seconds
- Accelerates granulation across multiple wound types
- Reduces the need for repeated debridements
- Supports antimicrobial stewardship by reducing unnecessary antibiotic use
Health-economic modeling predicts:
When added to standard of care, DEBRICHEM® leads to,
- Lower overall treatment costs
- Higher healing probability
AMCICHAC 2025: Official Launch
DEBRICHEM® will debut in Mexico at the 19th AMCICHAC International Wound Congress, taking place September 24–27, 2025, in León, Guanajuato. Launch activities will include a symposium with Miguel Ángel Mellado (Spain), a leading expert in advanced wound care. On September 26 at 7:00 AM at the Poliforum León, he will present “Novel Strategies for the Disruptive Balance Towards Healing,” sharing clinical insights on DEBRICHEM®’s role in improving outcomes.
Leadership Perspectives
Bert J. Quint, CEO of DEBx Medical:
"COFEPRIS approval marks an important milestone for DEBx Medical. With DEBRICHEM®, we are not only introducing an innovative solution but also reaffirming our long-term commitment to advancing wound care in Mexico."
Antonio Naim Soto, CEO of Biotechlives:
“The arrival of DEBRICHEM® in Mexico brings new hope to patients and their families, offering a faster path to healing and recovery. At Biotechlives, we believe this innovation will revolutionize wound care practices, empowering physicians to restore health, dignity and quality of life for those who need it most.”
Distribution and Rollout
Commercialization will be led by Biotechlives, with rollout beginning in Q4 2025. Backed by approval and strong partnership, DEBx Medical is looking forward to ease pressure on Mexico's healthcare system.
- We invite wound care professionals to connect with our team at AMCICHAC 2025, stop by the booth in Hall A206 or arrange a meeting in advance at info@debx-medical.com
- Request a free DEBRICHEM® demonstration at your clinic for 3-5 patients: https://www.debx-medical.com/request-a-demonstration/
About DEBx Medical
DEBx Medical is a leading innovator in advanced wound care solutions, dedicated to transforming the landscape of wound healing. With a focus on removing infection and biofilm, DEBx Medical pioneers groundbreaking solutions to address the unique challenges of hard-to-heal wounds. For more information, please visit: www.debx-medical.com.
About Biotechlives
Biotechlives SAPI is a Mexico-based healthcare company dedicated to bringing innovative medical technologies to clinicians and patients across the country. With a strong focus on advanced wound care and medical device distribution, Biotechlives partners with global innovators to introduce solutions that improve outcomes, reduce healthcare costs, and enhance quality of life.
Media Contact:
Chandrita Jaisinghani
Communications Manager, DEBx Medical
press@debx-medical.com | +31 85 0878096
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/342ff39c-63db-4317-afe4-cdcbe4cb0d92
DEBRICHEM® Works in 60 Seconds
Reopens the Pathway to Healing in Chronic Wounds
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
